No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CYTK Cytokinetics
- 59.230
- -0.910-1.51%
Close May 22 16:00 ET
- 51.340
- -7.890-13.32%
Post 19:59 ET
6.21BMarket Cap-10968P/E (TTM)
60.970High58.800Low1.50MVolume60.530Open60.140Pre Close84.39MTurnover1.44%Turnover RatioLossP/E (Static)104.85MShares110.25052wk High-15.68P/B6.17BFloat Cap25.98052wk Low--Dividend TTM104.14MShs Float110.250Historical High--Div YieldTTM3.61%Amplitude3.050Historical Low56.289Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline
Cytokinetics (CYTK) disclosed a collaboration late Wednesday under which Royalty Pharma (RPRX) will provide capital totaling up to $575 million to support the commercialization of aficamten and advanc
Cytokinetics Falls 10% on Royalty Pharma Transaction, Stock Offer
By Josh Beckerman Cytokinetics shares were down 10%, to $53.25, after hours as the biopharmaceutical company announced an expanded funding collaboration with Royalty Pharma totaling up to $575 millio
J.P. Morgan, Goldman Sachs Among Managers for Cytokinetics Offering >CYTK
J.P. Morgan, Goldman Sachs Among Managers for Cytokinetics Offering >CYTK
Cytokinetics Offering Is Expected to Close on May 28 >CYTK
Cytokinetics Offering Is Expected to Close on May 28 >CYTK
Cytokinetics Expects to Raise About $500M in Gross Proceeds >CYTK
Cytokinetics Expects to Raise About $500M in Gross Proceeds >CYTK
Cytokinetics Has Granted Underwriters Option for Additional 1,470,588 Shares >CYTK
Cytokinetics Has Granted Underwriters Option for Additional 1,470,588 Shares >CYTK
Comments
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x % $Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
3
CEO's belief in the company's potential to grow independently may have led to a 3% stock dip. Speculation around a Novartis takeover, and its withdrawal, could have swayed investor sentiment.
1
I'm going to try something new. I'm going to make a Sunday post so that it can be read before the market opens. I hope to still do my update before the market opens on Monday, I always want to see how futures move overnight.
This new thing I'm trying will be some random thoughts about the market. How to use some features on moomoo (a request by some) to do research and develop trading levels. To show this I will introduce some stocks iam in or will be starting positions in.
...
This new thing I'm trying will be some random thoughts about the market. How to use some features on moomoo (a request by some) to do research and develop trading levels. To show this I will introduce some stocks iam in or will be starting positions in.
...
+36
55
18
Truist analyst Srikripa Devarakonda views the recent weakness in Cytokinetics' stock as a buying opportunity and maintains a buy rating and $86 price target on the stock. Devarakonda continues to see Cytokinetics as a potential M&A target.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg